Moderna Announces Positive Top Line Data from Phase 2/3 Study of

MRNA: Moderna, Inc.
2021-10-25 08:30:00
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
Beyond Technical Analysis

כתב ויתור